DABIGATRAN ETEXILATE ZENTIVA K.S. 110 mg, hard capsule 60 capsules
Active ingredients: DABIGATRAN ÉTEXILATE, MÉSILATE DE DABIGATRAN ÉTEXILATE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DABIGATRAN ETEXILATE ZENTIVA K.S. 110 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 60 plaquettes prédécoupées unitaires aluminium OPA : polyamide orienté PVC de 1 gélule
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66272549CIP73028937CIP133400930289372Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DABIGATRAN ÉTEXILATEgélule | 110 mg · une gélule | FT |
| MÉSILATE DE DABIGATRAN ÉTEXILATEgélule | 126,83 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: DABIGATRAN ETEXILATE (MESILATE DE) équivalant à DABIGATRAN ETEXILATE 110 mg - PRADAXA 110 mg, gélule